Inhaled Corticosteroids Most Effective For Persistent Asthma In Children

Posted 2 months, 2 weeks ago at 11:10 am. 0 comments

While both inhaled corticosteroids (ICS) and leukotriene receptor antagonists (LTRA) must been proven to help control kind-to-steady persistent asthma in school-length of existence children, a fresh review shows ICS may be the more effective treatment.

Rejoinder Profiles to Fluticasone and Montelukast in Mild-to-Alleviate Persistent Childhood Asthma is featured in the January 2006 issue of the Journal of Allergy & Clinical Immunology (JACI) and is currently at one’s fingertips on the JACI’s Web situation at www.jacionline.org. The JACI is the colleague-reviewed, precise journal of the American Academy of Allergy, Asthma and Immunology (AAAAI).

The 16-week study was conducted as a multi-center, double-masked, 2-set crossover trial by the National Understanding, Lung and Blood Institute (NHLBI) Childhood Asthma Research and Education (CARE) Network. Researchers, led by Robert S. Zeiger, MD, PhD, from the University of California San Diego Department of Pediatrics, administered an ICS (fluticasone propionate) twice daily or an LTRA (montelukast) night after night to more than 100 children ages 6 to 17 who had mild-to-cool persistent asthma.

Researchers found both fluticasone and montelukast led to significant improvements in many measures of asthma mastery. Yet, compare favourably with to earlier research, they establish strong sign of greater mean improvements after 8 weeks of remedy with an ICS compared with a LTRA across many other outcomes.

Patients taking ICS experienced more asthma control days (ACD) in which they had no daytime or evening measure asthma symptoms, along with better pulmonary responses and inflammatory biomarkers. As a comparison, 29.3 % of participants had at least one more ACD per week during treatment with fluticasone than during treatment with montelukast (12.2 %).

To suss out an allergist/immunologist in your region, call the AAAAI Physician Referral and Information Way at (800) 822-2762 or stop in the AAAAI Web site at http://www.aaaai.org.

The AAAAI is the largest professional medical specialty organization in the Synergistic States representing allergists, asthma specialists, clinical immunologists, allied health professionals and others with a special interest in the research and treatment of allergic disease. Allergy/immunology specialists are pediatric or internal physic physicians who have elected an additional two years of training to become specialized in the treatment of asthma, allergy and immunologic disease. Established in 1943, the AAAAI has more than 6,000 members in the United States, Canada and 60 other countries. The AAAAI serves as an backer to the public by providing educational information through its Web place at http://www.aaaai.org .

Karen Janka
kjanka@aaaai.org
American Academy of Allergy, Asthma & Immunology
http://www.aaaai.org